PURPOSE: To examine patterns of health and symptoms associated with the initiation of adjuvant endocrine therapy (ET) for primary breast cancer treatment. PATIENTS AND METHODS: The mind-body study (MBS) observational cohort participants provided self-reported data on physical and mental health, ET-related symptoms, as well as depression, fatigue, and sleep obtained at enrollment (after primary treatment, prior to initiation of ET) and 6 and 12 months later. Longitudinal trajectories of outcome variables among three patient groups (no ET, aromatase inhibitor [AI], or tamoxifen) were compared by using linear mixed models. RESULTS: Two-thirds of the 186 women initiated ET, which was evenly split between AI and tamoxifen, and no significant differences were observed in self-reported measures among the groups at baseline or in covariate-adjusted analyses. Physical health scores were below normative levels initially and improved over time, but the AI group had a significantly lower score at 12 months (P = .05); mental health scores were within the normal range, were similar in each group, and did not change over time. The no-ET group showed either stable or declining symptom severity, whereas the ET groups often showed increased severity over time, and the AI group reported more severe musculoskeletal (P = .02), hot flash (P = .02), and cognitive problems (P = .006) at one or both of the follow-up time points compared with the no-ET group. The tamoxifen group had higher levels of hot flashes (P = .002), cognitive problems (P = .016), and bladder problems (P = .02) than the no-ET group. CONCLUSION: Attention should be given to the increased symptom burden associated with ET, and better efforts should be made to address patient-reported outcomes.
PURPOSE: To examine patterns of health and symptoms associated with the initiation of adjuvant endocrine therapy (ET) for primary breast cancer treatment. PATIENTS AND METHODS: The mind-body study (MBS) observational cohort participants provided self-reported data on physical and mental health, ET-related symptoms, as well as depression, fatigue, and sleep obtained at enrollment (after primary treatment, prior to initiation of ET) and 6 and 12 months later. Longitudinal trajectories of outcome variables among three patient groups (no ET, aromatase inhibitor [AI], or tamoxifen) were compared by using linear mixed models. RESULTS: Two-thirds of the 186 women initiated ET, which was evenly split between AI and tamoxifen, and no significant differences were observed in self-reported measures among the groups at baseline or in covariate-adjusted analyses. Physical health scores were below normative levels initially and improved over time, but the AI group had a significantly lower score at 12 months (P = .05); mental health scores were within the normal range, were similar in each group, and did not change over time. The no-ET group showed either stable or declining symptom severity, whereas the ET groups often showed increased severity over time, and the AI group reported more severe musculoskeletal (P = .02), hot flash (P = .02), and cognitive problems (P = .006) at one or both of the follow-up time points compared with the no-ET group. The tamoxifen group had higher levels of hot flashes (P = .002), cognitive problems (P = .016), and bladder problems (P = .02) than the no-ET group. CONCLUSION: Attention should be given to the increased symptom burden associated with ET, and better efforts should be made to address patient-reported outcomes.
Authors: Stephanie R Land; D Lawrence Wickerham; Joseph P Costantino; Marcie W Ritter; Victor G Vogel; Myoungkeun Lee; Eduardo R Pajon; James L Wade; Shaker Dakhil; James B Lockhart; Norman Wolmark; Patricia A Ganz Journal: JAMA Date: 2006-06-05 Impact factor: 56.272
Authors: Cornelis J H van de Velde; Daniel Rea; Caroline Seynaeve; Hein Putter; Annette Hasenburg; Jean-Michel Vannetzel; Robert Paridaens; Christos Markopoulos; Yasuo Hozumi; Elysee T M Hille; Dirk G Kieback; Lina Asmar; Jan Smeets; Johan W R Nortier; Peyman Hadji; John M S Bartlett; Stephen E Jones Journal: Lancet Date: 2011-01-22 Impact factor: 79.321
Authors: Lesley J Fallowfield; Judith M Bliss; Lucy S Porter; Miranda H Price; Claire F Snowdon; Stephen E Jones; R Charles Coombes; Emma Hall Journal: J Clin Oncol Date: 2006-02-20 Impact factor: 44.544
Authors: David Cella; Stephanie R Land; Chih-Hung Chang; Richard Day; Joseph P Costantino; Norman Wolmark; Patricia A Ganz Journal: Breast Cancer Res Treat Date: 2007-09-13 Impact factor: 4.872
Authors: Nicole J Gervais; Luke Remage-Healey; Joseph R Starrett; Daniel J Pollak; Jessica A Mong; Agnès Lacreuse Journal: J Neurosci Date: 2018-12-26 Impact factor: 6.167
Authors: Icro Meattini; Isacco Desideri; Giulio Francolini; Agnese Vannini; Marco Perna; Pietro Garlatti; Roberta Grassi; Lorenzo Livi Journal: Med Oncol Date: 2017-03-31 Impact factor: 3.064
Authors: Judith E Carroll; Kathleen Van Dyk; Julienne E Bower; Zorica Scuric; Laura Petersen; Robert Schiestl; Michael R Irwin; Patricia A Ganz Journal: Cancer Date: 2018-11-26 Impact factor: 6.860
Authors: Catherine M Bender; John D Merriman; Susan M Sereika; Amanda L Gentry; Frances E Casillo; Theresa A Koleck; Margaret Q Rosenzweig; Adam M Brufsky; Priscilla McAuliffe; Yehui Zhu; Yvette P Conley Journal: Oncol Nurs Forum Date: 2018-05-01 Impact factor: 2.172
Authors: Ilufredo Y Tantoy; Bruce A Cooper; Anand Dhruva; Janine Cataldo; Steven M Paul; Yvette P Conley; Marilyn Hammer; Kord M Kober; Jon D Levine; Christine Miaskowski Journal: Qual Life Res Date: 2018-04-21 Impact factor: 4.147
Authors: Larissa N Dooley; Patricia A Ganz; Steve W Cole; Catherine M Crespi; Julienne E Bower Journal: J Affect Disord Date: 2016-03-02 Impact factor: 4.839